Salute e Benessere

RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC ("Bidco") which is…

MANHATTAN BEACH, Calif., June 7, 2024 /PRNewswire/ -- On 24 May 2024, Bidco and K1 announced that the offer document (the "Offer Document") in relation to Bidco's offer to acquire the entire issued and to be issued share capital of MariaDB plc (the "Offer") had been published and posted to shareholders of MariaDB plc. MANHATTAN BEACH, Calif.,June 7, 2024/PRNewswire/ -- On24 May 2024, Bidco and K1 announced that the offer document (the " Offer Document ") in relation…
PR Newswire
07/06/2024

Oxurion Receives Transparency Notification from Atlas Special Opportunities…

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on June 7, 2024, from Atlas Special Opportunities, LLC indicating that as of June 7, 2024, it held...
Nasdaq GlobeNewswire
07/06/2024

PHAXIAM announces the availability of the preparatory documents for the Combined…

Lyon (France) and Cambridge (MA, US), 7 June 2024 - 5.45pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections,today announced the availability of preparatory documents for the Combined General Meeting of 28 June 2024. Shareholders of PHAXIAM Therapeutics are invited to attend the Combined General Meeting to be held on 28 June 2024 at 9:30 a.m. at the Company's registered...
Nasdaq GlobeNewswire
07/06/2024

ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia…

ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), and, together with its affiliates, currently holds more than 5% of Aurinia's common stock. ILJIN SNT Co., Ltd. (" ILJIN ") is a long-standing investor of Aurinia Pharmaceuticals Inc. (" Aurinia " or the " Company "), and, together with its affiliates, currently holds more than 5% of Aurinia's common stock. As one of…
PR Newswire
07/06/2024

deCODE genetics: The rate, nature and transmission of mitochondrial DNA…

Strong aggregate evidence was uncovered for selection against many such short-lived deleterious mtDNA mutations in the pedigrees. The deCODE team also reported evidence for an extensive earlier episode of negative selection affecting mitochondria, called germline selection, where poorly functioning mitochondrial DNA molecules are discarded during the development of oocytes. Finally, they used the large number of transmissisons of mtDNA mutations in the pedigrees to reliably estimate that…
PR Newswire
07/06/2024

Five-year data for Roche's Evrysdi show the majority of treated children with a…

After five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past two years of age96% of Evrysdi-treated children could swallow, 80% could feed without a feeding tube and 59% could sit without support for at least 30 seconds Evrysdi is now approved in more than 100 countries with over 15,000 patients treated globallyBasel, 07 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new five-year data...
Nasdaq GlobeNewswire
07/06/2024

By 2029, the Autologous Stem Cell & Non-stem Cell Therapies Market is forecasted…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=837 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=837 Browse in-depth TOC on "Autologous Stem Cell & Non-stem Cell Therapies Market" 326 - Tables 49 - Figures 309 - Pages In 2023, autologous non-stem cell therapies held the largest share of the type segment in the autologous stem cell & non-stem cell therapies market. Autologous non-stem cell...
PR Newswire
07/06/2024

Abu Dhabi is Underway to Become a Global Pharmaceutical and Life Science…

In line with the Abu Dhabi Economic Vision 2030, the MoU is a pivotal step in Abu Dhabi's ongoing efforts to become a leading healthcare destination in the global healthcare landscape. The strategic partnership aims to create attractive value propositions for pharmaceutical, biotechnology, and medical technology companies to establish their operations in Abu Dhabi. By capitalising on DoH's world-class regulatory framework, ADIO's attractive investment platform, Etihad Cargo's expertise in air…
PR Newswire
07/06/2024

IONETIX Produces First Batch of Actinium-225

"Commercial cyclotron-produced Ac-225 is a first, and a pivotal milestone for our alpha isotope program and the radiotherapeutic industry," said David Eve, VP of Medical Affairs at IONETIX. "The demand for alpha emitters is surging and this will allow researchers and drug developers to access these crucial isotopes to support their drug development work." "Commercial cyclotron-produced Ac-225 is a first, and a pivotal milestone for our alpha isotope program and the…
PR Newswire
07/06/2024

ZINZINO AB (PUBL): Zinzino now seeks acquisitions in the US and Asia to increase…

The United States accounts for Zinzino's third largest market share today and is also the leading direct sales market in the world, two decisive factors for why Zinzino is now actively looking to gain more traction in the US. Dag Bergheim Pettersen and his team have not set any specific geographic preferences within the US and are scouting targets on their own, drawing on their large network of contacts without taking financial advice to conduct the search. Dag Bergheim Pettersen does his own…
PR Newswire
07/06/2024

Zealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates…

Company announcement - No. 30 / 2024Zealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosisNews builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%).New data on the secondary endpoint shows up...
Nasdaq GlobeNewswire
07/06/2024

Boehringer Ingelheim's survodutide shows breakthrough improvement in liver…

News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%).New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH. 1 Additional sub-analysis shows up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an...
Nasdaq GlobeNewswire
07/06/2024

IMOU Launches New Cordless Camera Cell 3C Series

IMOU wireless security cameras are ideal for outdoor security settings without power. Designed to ensure users spend less money and less time, Cell 3C series are easy to install and features a large 5000mAh battery providing up to 120 days of protection on a single charge. Cell 3C Kit and All In One integrates a 3W solar panel that results in less charging and less security concern, whilst minimizing environmental impact. IMOU wireless security cameras are ideal for outdoor security settings...
PR Newswire
07/06/2024

Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia…

"We are pleased to share preliminary findings indicating promising results. Patients have reported improvements in both the number of Parkinson's disease symptoms and their overall quality of life. Furthermore, we have observed a notable reduction in resting tremor. While the precise data are still under rigorous evaluation, we remain cautiously optimistic about the potential implications of these outcomes," states Prof.David Skoloudik, MD, Ph.D.,FESO, FEAN, the study's lead and...
PR Newswire
07/06/2024

Department of Health - Abu Dhabi and Novartis to Partner to Advance Genomics…

This collaboration will utilise Abu Dhabi's genomics expertise and its future-forward, agile regulatory framework research hub to collaborate on future clinical research and the generation of RWE. This will include exploration of innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience. The two will also work together to generate and disseminate evidence to support the awareness and understanding of RLT – a form of precision nuclear medicine that may…
PR Newswire
07/06/2024

Alvotech Announces Strategic Refinancing Agreement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the successful arrangement of a strategic refinancing transaction. The financing, led by GoldenTree Asset Management, with participation from other institutional investors (collectively, the “Lenders”), will enable Alvotech (the “Company”) to improve cost of capital, address upcoming debt maturities in 2025 and enhance its financial...
Nasdaq GlobeNewswire
07/06/2024

3 Major Product Releases at 3Shape Discover Event

"Professionals seeking a lower-priced scanner should never compromise on the essentials like accuracy and usability. That's what makes our new TRIOS Core intraoral scanner so exciting. TRIOS Core packs 3Shape core scanning technology and a seamlessly integrated workflow with treatment partners in our most affordable scanner to date," says Jakob Just-Bomholt, 3Shape CEO. "Professionals seeking a lower-priced scanner should never compromise on the essentials like accuracy and…
PR Newswire
07/06/2024

The European Patent Office announces that a Tunisian team has been selected as a…

While studying at the Higher Institute of Medical Technologies of Tunis, the young team developed the MOOVOBRAIN system after one of the team had a family member struck with a sudden disability. This highlighted the urgent need for more adaptable assistive technologies. While studying at the Higher Institute of Medical Technologies ofTunis, the young team developed the MOOVOBRAIN system after one of the team had a family member struck with a sudden disability. This highlighted theurgent...
PR Newswire
07/06/2024

MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New…

TML-6 is a novel synthetic curcumin analog. Professor Ih-Jen Su at Southern Taiwan University used a platform of 6 aging and AD biomarkers to screen the 12 compounds from Androscience (San Diego, USA) for AD candidate. Preclinical studies showed that TML-6 (ASC-6) exhibits a multi-target action mechanism for AD, including anti-aging, activation of autophagy (mTOR inhibitor), reducing amyloid accumulation, and anti-inflammation (Figure 1), the efficacy confirmed by 2 AD animal models. TML-6 has a…
PR Newswire
07/06/2024

Insider Information: Nexstim Plc Announces Planned Alzheimer's Collaboration…

Company announcement, Helsinki, 7 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Announces Planned Alzheimer's Collaboration with Sinaptica Therapeutics, Inc. Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has successfully negotiated and signed a Letter of Intent (LOI) to exclusively collaborate with Sinaptica Therapeutics, Inc. (“Sinaptica”) to develop, manufacture and supply Sinaptica's patented precision neuromodulation system custom-based…
Nasdaq GlobeNewswire
07/06/2024

ELFBAR and LOST MARY to Unveil New Innovations at Dubai World Vape Show 2024

The brands will also leverage the trade fair to explore new partnership opportunities with distributors and retailers worldwide. The brands will also leverage the trade fair to explore new partnership opportunities with distributors and retailers worldwide. The occasion marks LOST MARY's office premiere in the UAE market. LOST MARY is now one of the leading vape brands globally in dozens of markets. Since their inception in 2018 and 2021, ELFBAR and LOST MARY have been at the forefront of...
PR Newswire
07/06/2024

Ipsen and Marengo Therapeutics announce second strategic partnership to advance…

Using Marengo's TriSTAR platform, Ipsen and Marengo teams expand their ongoing oncology research to include up to two additional assets in new early development collaborationResearch will focus on using Marengo's TriSTAR platform to reinvigorate and mobilize selective Vβ T cells to boost anti-tumor activity in patients with traditionally difficult-to-treat 'cold' tumorsPARIS, FRANCE, and CAMBRIDGE, MA, U.S., 07 June 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) and Marengo...
Nasdaq GlobeNewswire
07/06/2024

Kanazawa University research: Sensing a biomarker

The procedure presented by Biyani and colleagues is new in two ways. The first is that it uses newly identified aptamers as molecules that can recognize and capture ADAR1. Aptamers are molecules consisting of sequences of (synthetic) DNA, RNA or other biomolecules that bind to a particular target molecule, in this case ADAR1. The second novelty lies in the use of a field-deployable electrochemical sensor DEPSOR (BioSeeds Corp.), which has the advantages of, apart from being fast and…
PR Newswire
07/06/2024

BioSenic announces 2023 full year results

PRESS RELEASE - REGULATED INFIRMATION BioSenic stopped the patient recruitment for its Phase 2b ALLOB trial in mid-2023.BioSenic has prepared a global restructuring plan covering the years 2024-2032 and will actively pursue follow-up actions.BioSenic expects to use the proceeds from anticipated future fundraising as a priority to progress its Phase 3 clinical trial in cGvHD.Mont-Saint-Guibert, Belgium, June 6, 2024, 9:00pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS),...
Nasdaq GlobeNewswire
06/06/2024
Altri  Comunicati